Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222884
Title: Comparison of the EPOS 2020 and POLINA 2.0 guidelines for indicating biologic treatment in adults with chronic rhinosinusitis and nasal polyps
Author: Golet, Mireia
Padullés Zamora, Núria
Portillo Medina, Alejandro
Caballero, José María
Muñoz Esquerre, Mariana
Sastre, Joaquín
Alobid, Isam
González Compta, Xavier
Keywords: Pòlips (Patologia)
Malalties del nas
Productes biològics
Malalties cròniques
Polyps (Pathology)
Nose diseases
Biological products
Chronic diseases
Issue Date: 15-Feb-2025
Publisher: Elsevier España
Abstract: Objective: To analyze the volume of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) to whom biologics would be prescribed based on the European and Spanish clinical practice guidelines, and to evaluate the impact that an increase of 1 required prior surgery (from 1 to 2) may have on the number of indications. Methods: Cross-sectional analysis evaluating the application of the European Position Paper on CRSwNP Guidelines (EPOS 2020) and the Spanish Consensus on the Management of CRSwNP Guidelines (POLINA 2.0) on an on-going prospective cohort study of consecutive patients with severe CRSwNP in a tertiary hospital. Results: For a total of 103 patients with severe CRSwNP, 57.3% met EPOS 2020 criteria for biological treatment, whereas only 32% met POLINA 2.0 criteria. However, if the number of surgeries required to prescribe a biological therapy is increased to 2, only 31.1% of the patients would have indication of biological treatment, in any of the two guidelines. Conclusions: The differences among the POLINA 2.0 and the EPOS 2020 guidelines appear to have an impact in the proportion of patients eligible for biological therapies, with the former being stricter. Increasing the number of prior surgeries required, reduces the proportion of patients eligible for monoclonal antibodies prescription.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.otorri.2025.512224
It is part of: Acta Otorrinolaringológica Española, 2025, vol. 76, num.4
URI: https://hdl.handle.net/2445/222884
Related resource: https://doi.org/10.1016/j.otorri.2025.512224
ISSN: 0001-6519
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
883040.pdf397.5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons